SCIPIO BIOSCIENCE – Trademark Portfolio
Entity Type: 99
SCIPIO BIOSCIENCE holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include REVGEL, SCIPIO, ASTERIA, and CYTONAUT. The owner is based in MONTROUGE.
ARC-EN-CIEL
17 RUE DE LA VANNE
MONTROUGE 92120 , FR
Showing of trademarks Trademarks
Trademark Classifications
SCIPIO BIOSCIENCE's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does SCIPIO BIOSCIENCE have?
SCIPIO BIOSCIENCE has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does SCIPIO BIOSCIENCE file in?
SCIPIO BIOSCIENCE files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are SCIPIO BIOSCIENCE's most well-known trademarks?
SCIPIO BIOSCIENCE's registered trademark portfolio includes well-known marks such as REVGEL, SCIPIO, ASTERIA, and CYTONAUT. These are among 4 currently registered trademarks in the portfolio.
What is SCIPIO BIOSCIENCE's trademark registration success rate?
SCIPIO BIOSCIENCE has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.